Refractory Malignant Solid Neoplasm
Showing NaN - NaN of 32
Recurrent Malignant Solid Tumor, Recurrent Osteosarcoma, Refractory Malignant Solid Tumor Trial in United States (Laboratory
Active, not recruiting
- Recurrent Malignant Solid Neoplasm
- +3 more
- Laboratory Biomarker Analysis
- +2 more
-
Birmingham, Alabama
- +23 more
Apr 22, 2022
Advanced Lymphoma, Advanced Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Tumor Trial in Philadelphia (Taselisib)
Active, not recruiting
- Advanced Lymphoma
- +5 more
-
Philadelphia, PennsylvaniaECOG-ACRIN Cancer Research Group
Feb 4, 2022
Advanced Lymphoma, Advanced Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Tumor Trial in Philadelphia (Crizotinib)
Active, not recruiting
- Advanced Lymphoma
- +5 more
-
Philadelphia, PennsylvaniaECOG-ACRIN Cancer Research Group
Feb 4, 2022
Advanced Lymphoma, Advanced Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Tumor Trial in Philadelphia (FGFR Inhibitor
Completed
- Advanced Lymphoma
- +5 more
- FGFR Inhibitor AZD4547
-
Philadelphia, PennsylvaniaECOG-ACRIN Cancer Research Group
Jun 8, 2021
Childhood Solid Tumor, Recurrent Malignant Solid Tumor, Recurrent Primary CNS Tumor Trial in United States (Laboratory Biomarker
Completed
- Childhood Solid Neoplasm
- +4 more
- Laboratory Biomarker Analysis
- +2 more
-
Birmingham, Alabama
- +20 more
Apr 12, 2021
Advanced Lymphoma, Advanced Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Tumor Trial in Philadelphia (Nivolumab)
Completed
- Advanced Lymphoma
- +5 more
- Nivolumab
-
Philadelphia, PennsylvaniaECOG-ACRIN Cancer Research Group
Mar 15, 2021
Advanced Lymphoma, Advanced Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Tumor Trial in Philadelphia (Dasatinib)
Withdrawn
- Advanced Lymphoma
- +5 more
-
Philadelphia, PennsylvaniaECOG-ACRIN Cancer Research Group
Jul 17, 2020